Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors

There has been a significant shift in the management of B cell malignancies over the past decade. Initial strategies involving the use of systemic chemotherapies have been gradually replaced by more targeted therapies to improve survival and overall tolerability. Bruton's tyrosine kinase inhibitors are breakthrough drugs that have been approved to treat many B cell malignancies. Despite their demonstrated benefits, unintended events still occur including various cardiotoxicities. In this review, we discuss the rationale behind developing these agents, their common cardiovascular toxicities, and associated management challenges.

Keywords: Atrial fibrillation; BTK inhibitor; Cardio-oncology; Cardiotoxicity; Ibrutinib.